markets.businessinsider.com
Cure8 news brief
Why This Matters
If confirmed in later trials, a new TL1A‑targeting antibody could add a novel mechanism for patients with UC or Crohn’s who do not respond adequately to current therapies. Durable clinical and endoscopic responses over 44 weeks could indicate meaningful symptom control and mucosal healing.
Who Should Pay Attention
Adults with moderate‑to‑severe UC or Crohn’s disease, patients who have failed or lost response to approved therapies, clinicians treating IBD, and researchers focused on IBD drug development and biomarkers.
Study Snapshot
Story typePress release
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
The RELIEVE UCCD LTE enrolled patients who responded to a 14‑week induction and randomized 130 responders to two maintenance doses (450 mg or 900 mg subcutaneously every 4 weeks).
Reported outcomes at Week 44 included clinical remission and response (modified Mayo Score) and endoscopic improvement in UC, and endoscopic response (SES‑CD) plus CDAI clinical response and remission in CD. Results were described as numerically higher at the 900 mg dose.
Safety was consistent with induction and no new safety signals were reported; most adverse events were mild or moderate. Data scope and limits: This report is a company press release summarizing phase 2b LTE results presented at a conference.
The article provides descriptive efficacy rates with confidence intervals but does not include full trial datasets, peer‑reviewed publication details, or long‑term safety beyond 44 weeks. Presented biomarker findings are mentioned but not fully detailed here.
Keep In Mind
This is a company press release presented at UEG Week summarizing phase 2b long‑term extension data; results are descriptive and based on responders from the induction study. Peer‑reviewed publication and phase 3 data are needed to confirm efficacy and safety.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmarkets.businessinsider.com
Authorsmarkets.businessinsider.com
Indexed viaGoogle News
Source typeWeb article
PublishedOct 20, 2026, 12:20 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Novel Immunological-Directed Live Biotherapy Product for Treating Crohn's Disease
This project could introduce a novel, microbiome-targeted oral therapy for Crohn’s disease if the Phase II trial confirms safety and clinical benefit; that matters because many patients need new options when current...
PALI: PALI-2108 advances in IBD with pivotal UC trial and Crohn's study set for key ...
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease.
Bidirectional Brain-Gut Signaling in the Persistence of IBS-like Symptoms in Inflammatory Bowel Disease
Many people with IBD have ongoing IBS-like symptoms despite little or no intestinal inflammation. This project targets brain–gut and autonomic mechanisms that might explain symptom persistence and tests a non-drug...